Inoca 10mg Tablet contains Obeticholic acid, a potent farnesoid X receptor (FXR) agonist indicated for the treatment of primary biliary cholangitis (PBC) in adult patients with an inadequate response to ursodeoxycholic acid (UDCA) or as monotherapy in those intolerant to UDCA. Obeticholic acid works by modulating bile acid synthesis and transport, thereby reducing cholestasis and liver inflammation. The recommended dosage is 10mg once daily, with dose adjustments based on patient response and tolerability. Inoca 10mg is contraindicated in patients with complete biliary obstruction and should be used cautiously in those with advanced liver disease. Common adverse effects include pruritus, fatigue, abdominal pain, and headache, which are generally mild to moderate in severity. Liver function tests should be monitored regularly to assess therapeutic response and detect potential hepatotoxicity. Inoca 10mg should be prescribed under specialist supervision with appropriate clinical and laboratory monitoring. It is not recommended during pregnancy or breastfeeding unless the potential benefit outweighs the risk. Patients should be advised to report any worsening symptoms or adverse reactions promptly. This medication plays a critical role in managing PBC by improving biochemical markers and potentially delaying disease progression.